Low-Dose Multivalent saRNA Influenza Vaccine for Safer, Faster Protection
Official title: Low Dose Multivalent Influenza Vaccine via Modified Self-Amplifying RNA
Funded at Keylicon Biosciences INC · NIH-11311605 · Data updated 2026-11-12
A new low-dose self-amplifying RNA influenza vaccine that targets four flu antigens could offer quicker, stronger protection with fewer side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Keylicon Biosciences INC NIH-funded |
| Lab location | 1 site (Brookline, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $314,363 |
| NIH project number | 1R43AI197306-01 |
| Project ID | NIH-11311605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for seasonal influenza who would benefit from a safer, more scalable vaccine platform.
✕Less likely to help
People with allergies to vaccine components or certain immune conditions may not be suitable candidates.
What this research studies
This grant explores a multivalent self-amplifying RNA vaccine that encodes four WHO-recommended influenza antigens, aiming to provide lasting immune protection with a single low-dose shot. The project addresses manufacturing and supply challenges of current vaccines by leveraging saRNA to achieve higher protein output at very low doses. Researchers will investigate how nucleotide modifications affect immune activation and safety in human-relevant cells to minimize adverse responses while maximizing protection. The work builds on prior findings showing improved efficacy with specific RNA modifications in model systems and human cells.
Why it matters
Potential benefit: If successful, this approach could enable faster, more scalable flu vaccines that require smaller doses and potentially better protection.
How similar studies have gone: Earlier studies showed that modified saRNA can enhance protection and reduce unwanted immune responses in human cells and animal models.
Where this research is happening
-
Keylicon Biosciences INC
Brookline, United States Active
Researchers
- Principal investigator: Mcgee, Joshua — Keylicon Biosciences INC
- Study coordinator: Mcgee, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.